Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugated to proteinaceous toxin or fragment thereof
Reexamination Certificate
1998-03-19
2009-06-02
Helms, Larry R. (Department: 1643)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Conjugated to proteinaceous toxin or fragment thereof
C530S387100
Reexamination Certificate
active
07541034
ABSTRACT:
Methods and compositions relating to recombinant anti-CD22 antibodies with high binding affinity, and immunoconjugates comprising the anti-CD22 antibody linked to a therapeutic agent such as aPseudomonasexotoxin or a detectable label. The invention provides diagnostic methods, and means to inhibit the growth of malignant B cells.
REFERENCES:
patent: 4474893 (1984-10-01), Reading
patent: 4722899 (1988-02-01), Hamaoka et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5045451 (1991-09-01), Uhr et al.
patent: 5165923 (1992-11-01), Thorpe et al.
patent: 5258498 (1993-11-01), Huston et al.
patent: 5476659 (1995-12-01), Goodman et al.
patent: 5506126 (1996-04-01), Seed et al.
patent: 5618920 (1997-04-01), Robinson et al.
patent: WO94/29350 (1994-12-01), None
patent: WO 95/30004 (1995-11-01), None
patent: WO 98/41641 (1998-09-01), None
Kreitman et al ., Cancer Res. 53:819-825, 1993.
Kuan et al., Biochemistry 35:2872-2877, 1996.
Reiter et al., Biochemistry 33:5451-5459, 1994.
Chatterjee et al Cancer Immunol Immunother. 38:75-82, 1994.
Sevier et al., Clin Chem. 27:1797-1806, 1981.
Paul, Fundamental immunology, Raven Press, NY, Chapter 8, p. 242, 1993.
Kreitman et al., Proc. American Assoc. for Cancer REs. 38:28, 1997.
Amit et al., Science 233:747-753, 1986.
Rudikoff et al., PNAS 79:1979, 1982.
Panka et al., PNAS 85:3080-84, 1988.
Ghetie et al., Cancer Res. 51:5876-80, 1991.
George et al ., Molecular Sequencing ans Synthesis, Selected Methods and Applications Alan R. Liss, inc pp. 127-149, 1988.
Barton et al., Protein Structure Prediction, A Practical Approach, IRL Press pp. 31-63, 1996.
Greenspan et al., Nature Biotechnology 7:936-937, 1999.
Shen et al Int. J. Cancer 42:792-797, 1988.
Orlandi et al Proc. Natl. Acad. Sci USA 86:3833-37, 1989.
Ward et al., Nature 341:544-546, 1989.
Rudikoff et al (Proc Natl Acad Sci USA 1982 vol. 79 p. 1979, 1983.
Colman (Research in Immunology 145:33-36, 1994.
J. De Kruif et al.: “Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes.” FEBS Letters, vol. 399,, No. 3, Dec. 16, 1996, pp. 232-236, XP002075140 Amsterdam, NL.
D. Luo et al.: “V1-linker-Vh orientation-dependent expression of single chain Fv containing an engineered disulfide-stabilized bond in the framework regions.” Journal of Biochemistry, vol. 118, No. 4, Oct. 1, 1995, pp. 825-831, XP002075145 Tokyo, Japan.
E. Mansfield et al.: “Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies.” Bioconjugate Chemistry, vol. 7, No. 5, Sep. 1996, pp. 557-563, XP002075147 Washington, DC, USA.
E. Mansfield et al.: “Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.” Blood, vol. 90, No. 5, Sep. 1, 1997, pp. 2020-2026, XP002075148 New York, NY, USA.
V. Rajagopal et al.: “A form of anti-Tac(Fv) which is both single-chain and disulfide-stabilized for imaging CD25+ tumors.” Proceedings of the American Association for Cancer Research, vol. 8, Mar. 1997, p. 27 XP002075144 USA see abstract #180.
M. Rodrigues et al.: “Development of a humanized disulfide-stabilized anti-p185HER2 Fv-betalactamase fusion protein for activation of a cephalosporin doxorubicin prodrug.” Cancer Research, vol. 55, No. 1, Jan. 1, 1995, pp. 63-70, XP002075146 Baltimore, MD, USA.
Y. Reiter et al., “Engineering antibody Fv fragments for cancer detection and therapy: Disulfide-stabilized Fv fragments,”Nature Biotechnology(Oct. 1996) 14: 1239-1245.
Fitzgerald David J.
Kreitman Robert
Mansfield Elizabeth
Pastan Ira
Helms Larry R.
Natarajan Meera
The United States of America as represented by the Department of
Townsend and Townsend / and Crew LLP
LandOfFree
Recombinant antibodies and immunoconjugates targeted to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant antibodies and immunoconjugates targeted to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant antibodies and immunoconjugates targeted to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4077621